Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01689155 · ClinicalTrials.gov registry record
Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children
A clinical trial, sponsored by Sanofi Pasteur, a Sanofi Company.
- Completed
- Registry status
- 116
- Enrollment target
NCT01689155 is a clinical trial that has completed, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 116 participants.
The verdict
NCT01689155 has completed, sponsored by Sanofi Pasteur, a Sanofi Company.
- COMPLETED
- Registry status
- 116 participants
- Enrollment target
Study Summary
This is a passive-surveillance study that will accrue subjects for surveillance. For each accrued subject, surveillance for outcomes will continue for six months following the first dose. If a second dose is given within that time, then surveillance will be continued for six months following the second dose. Observational Objective: * To describe and characterize adverse events occurring after vaccination with Menactra vaccine.
Interventions
- BIOLOGICAL Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2011-06 |
| Est. Completion | 2016-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01689155
The ClinicalTrials.gov registry entry for NCT01689155 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate is the first listed.
NCT01689155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01689155 about?
NCT01689155 is a clinical study titled "Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children". This is a passive-surveillance study that will accrue subjects for surveillance. For each accrued subject, surveillance for outcomes will continue for six months following the first dose. If a second dose is given within that time, then surveillance will be continued for six months following the sec...
What is the current status of trial NCT01689155?
This trial is currently completed. The enrollment target is 116 participants. The study started on 2011-06. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01689155?
The interventions under investigation include: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (BIOLOGICAL).
Who is sponsoring clinical trial NCT01689155?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.